Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of...
18 insider purchases on record · latest filing 2021-03-31.
Insiders have also filed 316 sale transactions at RYTM.